SLS 005 Trehalose for ataxia

SLS-005 contains the active ingredient trehalose, a low molecular weight disaccharide (0.342 kDa) that has been shown to penetrate muscle and cross the blood brain barrier

On August 17, 2022 at 1 PM CDT, NAF is hosting a PrepRare Webinar featuring Dr. David Biondi, a Seelos Therapeutics physician. He will provide an overview of the STRIDES study which is currently open to patient recruitment in the United States. The overview will include background information on the Investigational drug, SLS-005, patient eligibility criteria, study center locations, and other important study design elements. You can register here: Meeting Registration - Zoom